It is uncertain if those with a serious mental illness (SMI) are more likely to have postacute sequelae of SARS-CoV-2 (PASC), given their greater susceptibility to COVID-19. Secondary prevention initiatives might benefit from an understanding of this connection. Thus, this study determined the risk that individuals with a SMI will acquire PASC.
Data from extensive electronic health records (EHRs) between March 2020 and April 2023, including a 180-day follow-up, were used in this longitudinal cohort research. Adults 21 years of age or older who had a proven COVID-19 infection as shown by a pertinent lab test, diagnosis, or prescription order were considered patients. Evidence of a diagnosis of schizophrenia, bipolar illness, or recurrent major depressive disorder prior to COVID-19 infection.
Evidence of PASC symptoms within 30 to 180 days of follow-up following COVID-19 infection was considered the primary outcome. It was given as odds ratios (OR) that were mutually adjusted for race age, sex, and ethnicity, insurance type, COVID-19 severity and Charlson Comorbidity Index (CCI) score.
1. A total of 1625 857 COVID-19-infected patients were included (mean [SD] age, 52 [17] years; 998 237 [61.4%] females, 204 237 [12.6%] non-Hispanic Black, 219 220 [13.5%] Hispanic, 833 411 [51.3%] non-Hispanic White, and 1 228 664 [75.6%] urban patients). 2. Of these, 258 523 (15.9%) had a SMI and 403 641 (24.8%) developed PASC). The adjusted chances of developing PASC were higher in those with a SMI (OR, 1.10; 95% CI, 1.08-1.11; P <.001).
3. Older age compared to age 22 to 34 years, non-Hispanic Black and Hispanic race and ethnicity compared to non-Hispanic White race and ethnicity (OR, 1.08; 95% CI, 1.07-1.10; OR, 1.12; 95% CI, 1.11-1.13), higher chronic disease burden when compared to no chronic disease (CCI 1 to 3: OR, 1.13; 95% CI, 1.12-1.14; CCI ≥4: OR, 1.23; 95% CI, 1.22-1.25), and hospitalization with initial COVID-19 infection.
4. Commercial health insurance was linked to decreased chances of PASC when compared to public insurance (OR, 0.85; 95% CI, 0.84-0.86). Overall, the necessity for coordinated mental health and COVID-19 care methods is highlighted by the fact that patients with SMI were more likely to develop PASC in this cohort analysis of COVID-19-infected individuals than those without SMI.
Source:
Vekaria, V., Thiruvalluru, R. K., Verzani, Z., Abedian, S., Olfson, M., Patra, B. G., Xiao, Y., Salamon, K. S., Hoth, K., Blancero, F., Hornig-Rohan, M. M., Akintonwa, T., Sabiha, M., Weiner, M. G., Carton, T. W., Kaushal, R., Pathak, J., & RECOVER PCORnet EHR consortium. (2025). Schizophrenia, bipolar, or major depressive disorder and postacute sequelae of COVID-19. JAMA Network Open, 8(10), e2540242. https://doi.org/10.1001/jamanetworkopen.2025.40242
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.